
Axonics Inc
NASDAQ:AXNX

Net Margin
Axonics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
US |
![]() |
Axonics Inc
NASDAQ:AXNX
|
3.6B USD |
-1%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
218.7B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.1B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
152.6B USD |
12%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
151B USD |
12%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
117.5B USD |
14%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
51.2B EUR |
9%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
52B USD |
7%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
44.9B USD |
75%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43B USD |
23%
|
|
US |
![]() |
Resmed Inc
NYSE:RMD
|
39.3B USD |
26%
|
Axonics Inc
Glance View
Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Axonics Inc's most recent financial statements, the company has Net Margin of -1.3%.